Highlights
- 1Disability and rehabilitation. Assistive technology · 2020
- 2Clinical neurology and neurosurgery · 2025
- 3
Publications
82 publications
Funding
14 grantsView NIH portfolio on RePORTER ↗
Active
9 grants- Co-IR01NS148533-01Development of An Integrated Pipeline for Early PD Prediction and Disease Modifying Drug RepurposingNational Institute of Neurological Disorders and Stroke · 2026–2031
- Co-IR01NS140142-01Progression Subtyping and Drug Target Identification for Parkinson's Disease with Integrative Machine LearningNational Institute of Neurological Disorders and Stroke · 2024–2029
- Co-I90REGE0028-01-00Enhance IIAdministration for Community Living · 2024–2029
- MPIU24NS107168-08Clinical Research Sites for the Network of Excellence in Neuroscience Clinical TrialsNational Institute of Neurological Disorders and Stroke · 2023–2028 · via Columbia University
- Co-IR01AG080624-01Disparities of Alzheimer's disease progression in sexual and gender minoritiesNational Institute on Aging · 2023–2028 · via University of Florida
- PIAPDA 255691-02APDA Referring CenterAmerican Parkinson Disease Association · 2025–2027
- Co-IR01AG080991-01Eligibility criteria design for Alzheimer's trials with real-world data and explainable AINational Institute on Aging · 2023–2027
- Co-IR01AG076234-01Computational Drug Repurposing for AD/ADRD with Integrative Analysis of Real World Data and Biomedical KnowledgeNational Institute on Aging · 2022–2027
- PIFF 227641-02Multidisciplinary Care for older adultsFan Fox & Leslie R. Samuels Foundation, Inc. · 2023–2025
Completed grants (5)
- PIPF-CG-1275176Increasing Utilization of Cognitive Behavioral Therapy for Insomnia (CBT-I) in a Group Setting with an App-based and Instructor- led CourseNational Parkinson Foundation · 2024–2025
- Co-IMJFF-023081Understanding the Progression Heterogeneity of Parkinson's Disease with Integrative Data-Driven Subtype AnalysisMichael J. Fox Foundation for Parkinson's Research · 2023–2025
- PIFFLSF 212363-02Psychosocial intervention as a critical component of multidisciplinary care for older adults with neurodegenerative disordersFan Fox & Leslie R. Samuels Foundation, Inc. · 2021–2024No publications yet
- Sub-PIU01NS114001-02NN110- A Dose Selection Trial of Light Therapy for Impaired Sleep in Parkinson’s DiseaseNational Institute of Neurological Disorders and Stroke · 2019–2023 · via The General Hospital Corporation (dba Massachusetts General Hospital)
- Co-IMJFF 14858Subtyping Parkinson’s Disease with Multi-Modal DataMichael J. Fox Foundation for Parkinson's Research · 2018–2018
Clinical research
33 studies
Active
15 studies- PINCT06996652An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)PHASE2 · Yale University · OPEN TO ACCRUAL (as of 2026)REM Sleep Behavior Disorder
- PIAI-Powered Eyewear for Analyzing Facial Expressions in Parkinson's Disease During Everyday ActivitiesWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2026)
- PINCT07304089A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia (Stride Dystonia)PHASE2 · Vima Therapeutics INC · OPEN TO ACCRUAL (as of 2026)Dystonia
- PINCT07174310A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's DiseasePHASE3 · F. Hoffman La-Roche Ltd · OPEN TO ACCRUAL (as of 2026)Parkinson's Disease
- PINCT07111663An Observational Study of Individuals With Isolated DystoniaVima Therapeutics INC · OPEN TO ACCRUAL (as of 2025)Isolated/Primary Dystonia That Affects More Than One Region of the Body
- PINCT06167681A Phase I/II Study to Assess the Safety, Tolerability and Efficacy of NouvNeu001 Injection for Mid- to Late-stage Parkinson's DiseasePHASE1; PHASE2 · iRegene Therapeutics CO LTD · OPEN TO ACCRUAL (as of 2025)Parkinson Disease
- PINCT06976268A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's DiseasePHASE2; PHASE3 · Biohaven Pharmaceuticals Inc., · OPEN TO ACCRUAL (as of 2025)Parkinson Disease
- PICombinatory microRNA and cfDNA serum and plasma signatures as classifiers of Parkinson's diseaseSt. John's University · OPEN TO ACCRUAL (as of 2025)
- PINCT06944522exPDite-2: A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy (Bemdaneprocel) for Participants With Parkinson's DiseasePHASE3 · BlueRock Therapeutics · OPEN TO ACCRUAL (as of 2025)Parkinsons Disease (PD)
- PINCT06975059Using the NUSHU Shoe to Analyze Gait Balance and Vibrotactile Feedback in Early, Moderate and Advanced PD Patients and Healthy ControlsNA · Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)Parkinson's Disease (PD)
- PINCT05894343Long-term Follow-up of Glutamic Acid Decarboxylase Gene Transfer to the Subthalamic Nuclei in Participants With Parkinson's DiseasePHASE1; PHASE2 · MeiraGTx, LLC · OPEN TO ACCRUAL (as of 2024)Parkinson's Disease
- PIContinued Evaluation of Patients With Parkinson’s Disease Who Previously Received BRT-DA01, a Human Embryonic Stem Cell-Derived Midbrain Dopaminergic Neuronal Cell Therapy - BRANYplus TransferBlueRock Therapeutics · OPEN TO ACCRUAL (as of 2023)
- PINCT04127578A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)PHASE1; PHASE2 · Prevail Therapeutics, Inc. · OPEN TO ACCRUAL (as of 2023)Parkinson Disease
- PINCT05418673A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122/DNL151 in Participants With Parkinson's Disease and Pathogenic LRRK2 VariantsPHASE3 · Biogen, Inc. · OPEN TO ACCRUAL (as of 2023)Parkinson Disease
- PIUtilizing Smartphone applications in Parkinson's Disease Management_x000D_Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2019)
Completed & closed trials (18)
- PINCT05348785A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's DiseasePHASE2 · Biogen, Inc. · IRB STUDY CLOSURE (as of 2026)Parkinson Disease
- PIA multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson's disease experiencing motor fluctuations (BouNDless)- SubstudyNeuroderm, Ltd. · IRB STUDY CLOSURE (as of 2026)
- PITRANSCEND 1 - An observational study of patients with moderate Parkinson's diseaseNovo Nordisk Pharmaceuticals, Inc. · IRB STUDY CLOSURE (as of 2026)
- PINCT06553027Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor ComplicationsPHASE3 · Cerevance Beta, Inc. · CLOSED TO ACCRUAL (as of 2026)Parkinson Disease
- PINCT05779475An Observational Study of Patients With Moderate Parkinson's DiseaseNovo Nordisk Pharmaceuticals, Inc. · IRB STUDY CLOSURE (as of 2026)Parkinson Disease
- PINCT04006210A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)PHASE3 · Neuroderm, Ltd. · IRB STUDY CLOSURE (as of 2025)Parkinson's Disease
- PINCT05924243A Phase 1b, Adaptive, Multi-Center, Randomized, Double Blind, Placebo-Controlled, Parallel Design Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's DiseasePHASE1 · F. Hoffman La-Roche Ltd · IRB STUDY CLOSURE (as of 2025)Parkinson Disease
- PINCT06055985A Multicenter Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's DiseasePHASE2 · UCB Biopharma SRL · IRB STUDY CLOSURE (as of 2025)Parkinson Disease
- PINCT06006247A Randomized, Double-Blind, Placebo-Controlled Trial of CVN424 in Early Parkinson's DiseasePHASE2 · Cerevance Beta, Inc. · IRB STUDY CLOSURE (as of 2025)Parkinson's Disease
- PINCT05603312A Randomized, Double-Blind, Sham-Controlled Study to Evaluate the Safety and Tolerability of Glutamic Acid Decarboxylase Gene Transfer to the Subthalamic Nuclei in Participants With Parkinson's DiseasePHASE1; PHASE2 · MeiraGTx, LLC · IRB STUDY CLOSURE (as of 2025)Parkinson's Disease
- PIPhase 1 Study To Assess the Safety and Tolerability of Human Embryonic Stem Cell-Derived Midbrain Dopamine Neuron Cell Therapy (MSK-DA01) For Advanced Parkinson's DiseaseBlueRock Therapeutics · IRB STUDY CLOSURE (as of 2025)
- PINCT05819359A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson's Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) GenePHASE2 · BIAL R&D Investments S.A. · CLOSED TO ACCRUAL (as of 2024)Parkinson's Disease
- PINCT03655236A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson's DiseasePHASE2 · Sun Pharmaceuticals Global FZE · IRB STUDY CLOSURE (as of 2024)Early Parkinson Disease
- PINCT04377945A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual ComponentsPHASE2 · Bukwang Pharmaceutical Co., Ltd. · IRB STUDY CLOSURE (as of 2024)Dyskinesias; Parkinson Disease
- PINCT05363046A Multi-center, Noninterventional Study Evaluating Variability, Reliability, and Compliance for the Parkinson's Disease DiaryBlueRock Therapeutics · CLOSED TO ACCRUAL (as of 2024)Parkinson's Disease
- PIGenotyping Patients with Parkinson's Disease as a Step Towards a Precision Medicine ApproachWeill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2023)
- PINCT04291014A Dose Selection Trial of Light Therapy for Impaired Sleep in Parkinson's DiseaseNA · The General Hospital Corporation (dba Massachusetts General Hospital) · IRB STUDY CLOSURE (as of 2023)Parkinson Disease; Sleep Disorder; Fatigue
- PIRetrospective Description of the Clinical Features of Patients with Parkinson?s Disease Presenting with DystoniaWeill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2021)
News mentions
1 mentionView all WCM news ↗
- Noninvasive Focused Ultrasound Treatment Can Ease Motor Symptoms of Parkinson’s DiseaseOctober 27, 2026
As Stan Au’s Parkinson’s disease symptoms progressed, everyday activities became daily battles. His hands shook so badly that he struggled to hold utensils and couldn’t sign his name. He stopped playing pickleball—a sport he once enjoyed—despite taking a widely prescribed medication for managing motor symptoms.
Media highlights
1 clip
- Cornell Profile Shows Benefits And Risks Of Ultrasound Treatment For Parkinson’sFingerLakes1.com · October 30, 2026
Mentoring
1 mentee
- HLHudson LeeMD mentee · Class of 2024
External relationships
Advisory/Scientific Board Member
AbbVie Inc.
Other
BlueRock Therapeutics